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Hepatic steatosis
Nonalcoholic fatty liver disease (NAFLD) 
is the ectopic accumulation of lipid in the 
liver parenchyma in the absence of alcohol 
overconsumption. Only recently defined 
as a distinct clinical entity, NAFLD has 
become the most common liver disease in 
many parts of the world (1, 2). Though the 
accumulation of intrahepatic triglycerides 
by itself may be relatively benign, hepat-
ic steatosis can progress to nonalcoholic 
steatohepatitis (NASH), which is charac-
terized by marked inflammation, hepato-
cyte death, and replacement with collagen 
matrix (fibrosis). Moreover, NAFLD and 
NASH are also associated with an increased 
risk of developing cirrhosis and hepatocel-
lular carcinoma (3). Although NAFLD and 
NASH have become exceedingly common, 
there are currently no FDA-approved thera-
pies for this spectrum of diseases, and, thus, 
treatments for NAFLD and NASH repre-
sent a significant unmet medical need.
Mouse models of NAFLD have been 
developed to study this disorder in geneti-
cally tractable organisms. In general, mice 
fed a fatty acid–enriched diet develop 
hepatic steatosis without coincident fibrosis 
or other signs of NASH (4). Diets enriched 
with fructose also produce intrahepatic lip-
id accumulation in rodents (5), and some 
epidemiologic studies support the notion 
that overconsumption of sugar-sweetened 
beverages containing high-fructose corn 
syrup can be connected to the development 
of NAFLD in humans as well (6). In mouse 
models, supplementation of high-fat or fruc-
tose diets with 1% to 2% cholesterol produc-
es liver injury reminiscent of human NASH 
(7), but the relevance of such high levels of 
cholesterol in the diet can be questioned.
In order for fructose and other sugars 
supplemented in the diet to contribute to 
complex lipids deposited in the liver, they 
must first be converted to fatty acids via 
de novo lipogenesis (DNL) (Figure 1). The 
carbon contained in fructose must be con-
verted to acetyl-CoA and then citrate in 
the mitochondrion before entering into 
the process of DNL in the cytosol. This 
complex process is mediated by a num-
ber of metabolic enzymes and regulated 
at both the transcriptional and posttrans-
lational levels. Transcriptionally, the 
genes encoding these myriad enzymes 
are regulated by the basic helix-loop- helix 
transcription factors sterol response ele-
ment–binding protein 1 (SREBP1c) and 
carbohydrate response element–binding 
protein (ChREBP), which are activated by 
insulin (8) and intermediates of carbohy-
drate metabolism (9), respectively.
Originally described as a glucose- 
responsive transcription factor, ChREBP 
has also been shown to be highly responsive 
to fructose in recent studies conducted in 
both rodents and humans (10). Indeed, in 
response to fructose feeding or an acute 
bolus of fructose, a ChREBP-dependent 
expression of the program of genes encod-
ing various lipogenic enzymes is induced 
in the liver (11, 12). Many of the genes in 
this pathway, including fatty acid synthase 
(Fasn), sterol-CoA desaturase (Scd1), and 
acetyl CoA carboxylase 1 (Acc1) (13), are 
not induced in response to fructose in mice 
lacking ChREBP. Moreover, knockdown 
or knockout of Chrebp prevents the devel-
opment of hepatic steatosis in models of 
fructose administration and in genetic 
models of obesity-related NAFLD (11, 12). 
However, there are also data suggesting 
that the induction of this gene program may 
play a protective role in liver, as mice lack-
ing ChREBP fail to thrive or even die when 
placed on extremely high-carbohydrate 
diets (13). Other studies have suggested 
that ChREBP-mediated induction of the 
hepatokine FGF21 in response to fructose 
(10) communicates with the CNS to reduce 
fructose consumption (14, 15). Moreover, it 
has been suggested that while activation of 
ChREBP promotes fat storage, it also miti-
gates the development of insulin resistance 
that is associated with NAFLD (16). Indeed, 
many obese human subjects remain meta-
bolically healthy, and it has been suggested 
that the capacity for lipogenesis may actu-
ally be increased in these obese, metaboli-
cally normal subjects compared with met-
abolically unhealthy individuals (17). The 
contribution of ChREBP to this phenome-
non, especially in liver, remains unclear.
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Overconsumption of fructose and other sugars has been linked to 
nonalcoholic fatty liver disease (NAFLD); however, the sugar-associated 
effects that lead to disease are poorly defined. In this issue of the JCI, Zhang 
and colleagues show that the carbohydrate response element–binding 
protein (ChREBP) coordinates an adaptive response to a high-fructose diet in 
mice and that loss of this transcription factor leads to hepatic inflammation 
and early signs of fibrosis. Intriguingly, ChREBP-dependent effects were due 
to an exaggerated activation of the proapoptotic arms of the endoplasmic 
reticulum stress response that is probably secondary to inappropriate 
derepression of cholesterol biosynthesis. These findings suggest that a 
previously unknown link exists between ChREBP and the regulation of 
cholesterol synthesis that affects liver injury.
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ic inflammation, development of fibrosis, 
and NASH (19, 23), and the addition of high 
levels of cholesterol to diets fed to rodents 
is particularly associated with the develop-
ment of hepatic fibrosis (7). Unexpectedly, 
Zhang et al. also determined that, while 
hepatic triglyceride content was reduced 
in Chrebp–/– mice in response to high-fruc-
tose feeding, hepatic cholesterol content 
was markedly increased, coincident with 
increased cholesterol biosynthesis. In 
the livers of WT mice fed a high-fructose 
diet, the expression of enzymes involved 
in cholesterol biosynthesis was actual-
ly decreased compared with expression 
in those fed a control diet. In contrast, 
Chrebp–/– mice failed to suppress hepatic 
cholesterol biosynthesis in response to a 
high-fructose diet; however, restoration 
of ChREBP expression in the livers of 
Chrebp–/– mice suppressed the induction 
of many genes involved in cholesterol bio-
synthesis and reduced free cholesterol lev-
els. In addition, suppression of cholesterol 
synthesis with atorvastatin attenuated liv-
er injury in Chrebp–/– mice. Thus, ChREBP 
may protect against fructose-induced liver 
injury, in part, by repressing cholesterol 
biosynthesis and cholesterol accumula-
tion. By using a model system without 
high amounts of added dietary cholesterol, 
Zhang and colleagues provide strong new 
evidence that cholesterol aggregation in 
the liver is a trigger for liver injury and pro-
gression to NASH.
Zhang and colleagues also demon-
strated that ChREBP directly interacts with 
SREBP2, which is the major transcription-
al regulator of genes involved in hepatic 
in WT mice fed the same diet. GRP78 is 
a chaperone protein that helps attenu-
ate ER stress (21) and has not previously 
been linked to ChREBP signaling. On the 
other hand, Chrebp–/– mice had increased 
activation of the protein kinase R–like 
endoplasmic reticulum kinase/activating 
transcription factor 4/C-EBP homology 
protein (PERK/ATF4/CHOP) pathway 
and induction of CHOP-mediated apopto-
sis on a high-fructose diet. Liver injury in 
fructose-fed Chrebp–/– mice could be coun-
teracted by adenovirus-mediated overex-
pression of GRP78, knockdown of CHOP, 
or administration of a chemical chaperone 
to attenuate ER stress. Together, these 
findings suggest that ChREBP is a fructose- 
responsive transcription factor that also 
fine-tunes the ER stress response and may 
promote activation of the adaptive arms in 
response to high-fructose concentrations, 
which can be a noxious stimulus.
Many lipid species are elevated in the 
livers of patients with NAFLD and have 
been implicated in the progression to 
NASH. Comparisons of plasma and hepat-
ic lipid levels have revealed an increase in 
triglycerides, diglycerides, ceramides, oth-
er complex lipids, free fatty acids, and cho-
lesterol in patients with NASH compared 
with those without NASH (22). Admitted-
ly, many of these lipids have been linked 
to metabolic abnormalities and NAFLD- 
associated liver injury; therefore, a case 
can be made or argued for many of these 
lipids as mediators of disease. Nonetheless, 
studies conducted in animal models and 
human studies have correlated high intra-
hepatic free cholesterol levels with hepat-
ChREBP and the response to  
a high-fructose diet
In this issue, Zhang and colleagues 
(18) have demonstrated that mice fed a 
high-fructose diet exhibit selective induc-
tion of ChREBP, but not SREBP1c, in the 
liver. Moreover, as previously described, 
mice lacking ChREBP were protected 
from high-fructose diet–induced increases 
in FASN, SCD1, and ACC1 expression in 
the liver and the development of hepat-
ic steatosis, suggesting that SREBP1c 
is not sufficient to mediate the adverse 
effects associated with a high-fructose 
diet. Despite being protected from liver 
triglyceride accumulation in response to 
fructose feeding, Chrebp–/– mice had unex-
pected increases in liver injury and hepato-
cyte apoptosis. ChREBP-deficient mice 
showed signs of early stages of fibrosis and 
NASH in response to fructose, while WT 
mice did not.
Apoptosis and inflammation are key 
features of progressive NASH and are both 
linked to the endoplasmic reticulum (ER) 
stress response (19). Under conditions of 
severe distress, ER stress signaling acti-
vates the apoptotic signaling cascade (20). 
However, other components of this coordi-
nated response actually represent adaptive 
responses to alleviate ER stress and are 
prosurvival. Zhang and colleagues found 
that a high-fructose diet failed to induce 
the adaptive arms of the ER stress response 
but heightened activation of the proapop-
totic signaling mediators of the ER stress 
pathway in Chrebp–/– mice. Notably, expres-
sion of GRP78 was reduced in fructose-fed 
Chrebp–/– mice compared with expression 
Figure 1. ChREBP senses fructose to coordinate 
a protective response in the liver. (A) Zhang et 
al. show that fructose-mediated activation of 
ChREBP in a normal liver results in increased 
DNL and promotes the degradation of SREBP2. 
This response is hepatoprotective, ultimately 
leading to an increase in hepatic triglyceride but 
no change in cholesterol levels. (B) On the other 
hand, mice lacking ChREBP do not accumulate 
excess triglycerides in their liver when fed a 
high-fructose diet. Because fatty acids and cho-
lesterol share a common precursor, acetyl-CoA, 
carbon in fructose may flux toward cholesterol 
synthesis. Moreover, SREBP2 is activated in 
ChREBP-deficient hepatocytes to yield elevated 
hepatic cholesterol levels that predispose to 
maladaptive ER stress signaling, apoptosis, and 
hepatic injury.
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important insight into an individual’s pre-
disposition to develop NAFLD/NASH in a 
given dietary context and allow for indi-
vidualized nutritional guidance.
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cholesterol biosynthesis, uptake, secre-
tion, and transport. Their data suggest that 
ChREBP directly interacts with SREBP2 
and that this interaction may promote the 
ubiquitination and subsequent degrada-
tion of SREBP2. This work, while quite 
preliminary and requiring repetition and 
validation without overexpression, sug-
gests the existence of a new mechanism for 
regulating SREBP2 activity. The teleologi-
cal or physiological reasons why this car-
bohydrate-responsive transcription factor 
would negatively regulate SREBP2 at this 
level remain unclear, but could represent 
a new mechanism of nutrient crosstalk. As 
both cholesterol and fatty acid synthesis 
require a common precursor (acetyl-CoA), 
it is possible that in the absence of ChREBP, 
some of the carbon that would have fluxed 
into the synthesis of new fatty acids is 
instead directed to flux toward cholesterol 
synthesis (Figure 1). This possibility will 
also need to be explored in future studies.
Concluding remarks
Taken with previous work, this study 
by Zhang et al. suggests that ChREBP 
plays an important protective role in the 
response to fructose overload. Many 
mechanistic questions remain unan-
swered in this initial report. For example, 
does ChREBP enhance SREBP2 ubiquiti-
nation by tethering a ubiquitin ligase to 
SREBP2 or by some other mechanism? 
Can ChREBP also regulate ubiquitination 
of other proteins that regulate fat metab-
olism, including SREBP1c, or is this effect 
specific to SREBP2? It also remains to be 
determined whether genetic variations in 
ChREBP may influence the response to 
fructose in humans or provide a potential 
mechanism to explain why some indi-
viduals are more likely to progress from 
steatosis to NASH when consuming diets 
rich in fructose. Identification of such a 
nutrient-gene interaction could provide 
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